The bottom line is that the discourse about Biogen with respect to xoma in SI, yahoo and the yahoo thread is full of intentional dishonest garbage from many with the only tribal need of defending anything xoma and attacking everything Biogen.
Mr Gw, still the cool one, is one of the few I answer back and/or try to reason with, and/or learn from cause We have followed xoma for many years, and on the same thread since 1997, I know a lot of his positions and He know many of mine. Sometimes We agree upon, many times We do not. Sometimes heat goes up, but no disrespect at all.
Since the thread has become a very limited few poster board, it is sometimes confusing to follow, sometimes the conversation is across several threads, even some that are not xoma, not Biogen.
He constantly finds my mistakes, real or imaginary ones, He does know I do not hear to CCs much, neither read in detail but what interest me much to make decisions which is the science part of the companies, in fact I relied on many of the other poster for the financials and particularly in Gw explanations of many of those issues.
In return, I constantly exposed his pro xoma bias and his antiBiogen prejudice, but never placing him with the yahoo garbage group. One of his unfair (but honest)view is his equating Biogen with the imcl and eln troubles to my astonishment, cause the quality of Biogen research, regulatory (fda)experience, deals, marketing, cash, sales, earnings and prospects are top ones on biotech and pharma.
He does know that I dislike most of the xoma staff, but He also knows that I credit (not that is important but to us) the xoma ceoperson for good management to save the company from dissapearing, and up to a point good for savvy investors that jump in and out on time after learning the rhythms of the company fortunes or misfortunes. Nevertheless, I did find disgusting their handling of the bpi meningococcemia affairs, especially the 18 months of quasi silence (full silence would have been better)except for pure hyping (not without leaving behind my own greed and fears and the resulting gains and/or losses, and appreciating the inside to learning to invest the experience gave me)and you could go back and read the last 9,000 posts and get a good idea.
But, no need to follow the 9,000 post reading tasks seriously, the summary is that I fear and predicted that Biogen will be a formidable competitor, only to be derised over and over, I predicted that Xanelim would be the driver of xoma success not the bpi platform (at least for the last 3 years)and that Biogen will lead (and coming from second they are now leaders)that Amevive will be approved (despite almost total disbelief from analyst pro and anti)based on the good clinical reports, that the side effects will not stop the drug from approval, and will not for marketing. And that xoma investement at any point MUST take into account Biogen's Amevive success (and it will) not the many times announced demise by the xoma fanatics that do not help to evaluate xoma decently.
I even proposed minimal values scenarios for xoma with reasonable attempts of valuation based on decent outcomes, only to get for response (most of the times)avoidance at best, insults at worst.
I follow xoma these days cause I own Biogen and Dna (traded then frequently in the last 2 years)and planning to keep investing in those two. And maybe attempt again to invest in xoma if I can time a good entrance (long or short, right now a long position is the place to be). I have already made money and lost money more as a long than as a short (few hundred shares short once only). Plus, the custom of following xoma.
I am still interested in the bpi platform for sepsis and especially for the retina program. The rest of the company science does not interest me cause I see little value on it.
I am highly combative in my views and oppinion, colorful, sarcastic, annoying, forceful and my english is convoluted at best. At the same time, I rarely insult a poster ( do insult their posts and they confused the issues, but hey it is not phylosophy), I learn avidly, respect most posters, ignore a lot of the garbage ones, and give my posting biography to certain weirdly interested ones that I do not know what do they (of I) get from it except as per Robert K for entertaining purposes only all dysclaimers do not apply.
xoma is worth $2 to $3 at this moment cause of the uncertainties, $6 with better clear data. Reasonable high risk at current $4 (my oppinion, of course).
By the way, what do you think about bpi prospects for newborns !
bpi for adult sepsis !!
or the bpi retina program !!!
Regards, |
